02055nas a2200253   4500000000100000008004100001653000900042653001700051653002700068653001900095653001400114653001300128653001000141100001200151700001400163700001200177700001100189245009100200856006600291300001200357490000900369520140900378022001401787       2017                            d10aNTDs10aBuruli ulcer10aMycobacterium ulcerans10aAntimicrobials10aTreatment10aisolates10aGhana1 aOwusu E1 aNewman MJ1 aAddo KK1 aAddo P00aIn Vitro Susceptibility of Mycobacterium ulcerans Isolates to Selected Antimicrobials.  uhttp://downloads.hindawi.com/journals/cjidmm/2017/5180984.pdf  a51809840 v20173 a<p>Background. The current definitive treatment of Buruli ulcer with antibiotics makes the issue of antimicrobial drug resistance an unavoidable one. This is as a result of drug misuse by health personnel and patients' noncompliance to treatment regimen. Monitoring of these factors and screening for new effective antimicrobials are crucial to effective management of Buruli ulcer disease. This study therefore investigated the inhibitory activity of some antibiotics against isolates of Mycobacterium ulcerans. Methods. Activity of eight antibiotics was tested against twelve M. ulcerans isolates (2 reference strains and 10 clinical isolates). The anti-M. ulcerans activities were determined by the agar dilution method and the minimum inhibitory concentrations (MICs) were determined by the agar proportion method. Results. All antimicrobials investigated had activity against M. ulcerans isolates tested. The MICs ranged from 0.16 μg/mL to 2.5 μg/mL. Azithromycin recorded the highest inhibitory activity at a mean MIC of 0.39 μg/mL, whilst clofazimine a second-line antileprosy drug, recorded the lowest at a mean MIC of 2.19 μg/mL. Among the four antituberculosis drugs, rifampicin had the highest activity with a mean MIC of 0.81 μg/mL. Conclusion. Azithromycin could be considered as a lucrative alternative to existing treatment methods for inhibiting M. ulcerans in Ghana.</p>
  a1712-9532